S134: INTRA-PATIENT FUNCTIONAL HETEROGENEITY OF AML DETERMINES FIRST-LINE TREATMENT RESPONSE

• Y. Severin,
• Y. Festl,
• M. Roiss,
• T. Benoit,
• T. Heinemann,
• R. Wegmann,
• A.-K. Kienzler,
• M. Bissig,
• M. Scharl,
• M. Manz,
• A. M. Müller,
• B. Snijder

Affiliations

Y. Severin

1 Institute of Molecular Systems Biology, ETH Zurich

Y. Festl

1 Institute of Molecular Systems Biology, ETH Zurich

M. Roiss

2 Medical clinic of Oncology and Haematology, University Hospital Zurich

T. Benoit

3 Medical clinic of Oncology and Haematology, University Hospital Zurich, Zürich, Switzerland

T. Heinemann

1 Institute of Molecular Systems Biology, ETH Zurich

R. Wegmann

1 Institute of Molecular Systems Biology, ETH Zurich

A.-K. Kienzler

3 Medical clinic of Oncology and Haematology, University Hospital Zurich, Zürich, Switzerland

M. Bissig

3 Medical clinic of Oncology and Haematology, University Hospital Zurich, Zürich, Switzerland

M. Scharl

3 Medical clinic of Oncology and Haematology, University Hospital Zurich, Zürich, Switzerland

M. Manz

3 Medical clinic of Oncology and Haematology, University Hospital Zurich, Zürich, Switzerland

A. M. Müller

3 Medical clinic of Oncology and Haematology, University Hospital Zurich, Zürich, Switzerland

B. Snijder

1 Institute of Molecular Systems Biology, ETH Zurich